Effects of using designated quasi-drugs on onychomycosis

Effects of using designated quasi-drugs on onychomycosis : single blinded study - Effects of using designated quasi-drugs on onychomycosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000058284

Enrollment

Registered

2025-06-27

Start date

2025-06-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subjects with onychomycosis

Interventions

Use test article on one foot only for 2 weeks No test article applied on the other foot

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects with onychomycosis on the nails of both right and left feet

Exclusion criteria

Exclusion criteria: 1. Subjects who are using onychomycotic medications 2. Subjects who are in the hospital or being treated by a doctor for athlete's foot. 3. Subjects with extensive affected areas, deep wounds or severe burns on the subject area. 4. Patients with a history of drug allergy. 5. Consumption or application of supplements or medications that may affect the efficacy of the test product. 6. Pregnant or lactating women 7. Participation in other human studies within one month.

Design outcomes

Primary

Measure	Time frame
image evaluation	—

Secondary

Measure	Time frame
Subjective evaluation	—

Countries

Japan

Contacts

Public ContactTakeshi Kaneko

Japan Clinical Trial Association N.A.

info@yakujihou.org0364574666

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026